Fotemustine: A third-generation nitrosourea for the treatment of recurrent malignant gliomas

Cancers

Volumn 4, Issue 1, 2012, Pages 77-87

  Beauchesne, Patrick ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Chemotherapy; Fotemustine; Malignant gliomas; Recurrent tumors; Salvage therapy; Second line treatment

Indexed keywords

BEVACIZUMAB; DACARBAZINE; FOTEMUSTINE; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BLINDNESS; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG WITHDRAWAL; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RECURRENT CANCER; REVIEW; STROKE; SURVIVAL TIME; THROMBOCYTOPENIA; VISUAL IMPAIRMENT;

EID: 84859089887     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010077     Document Type: Review

References (28)

1. Behin, A.; Hoang-Xuan, K.; Carpentier, A.F.; Delattre, J.Y. Primary brain tumours in adults. Lancet 2003, 361, 323-331.
2. de Angelis, L.M. Brain tumours. N. Engl. J. Med. 2001, 344, 114-123.
3. Fine, H.A.; Dear, K.B.; Loeffler, J.S.; Black, P.M.; Canellos, G.P. Meta-analysis of radiation with and without chemotherapy for malignant gliomas in adults. Cancer 1993, 71, 2585-2597.
4. Stewart, L.A. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002, 359, 1011-1018.
5. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
6. Lassman, A.; Iwamoto, F.; Cloughesy, T.; Aldape, K.; Rivera, A.; Eichler, A.; Louis, D.; Paleologos, N.; Fisher, B.; Ashby, L. et al. International retrospective study of over 1,000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 2011, 13, 649-659.
7. Stupp, R.; Hegi, M.E.; Gilbert, M.R.; Chakravarti, A. Chemotherapy in malignant glioma: Standard of care and future directions. J. Clin. Oncol. 2007, 25, 4127-4136.
8. Niyazi, M.; Siefert, A.; Schwarz, S.B.; Ganswendt, U.; Kreth, F.W.; Tonn, J.C.; Belka, C. Therapeutic options for recurrent malignant gliomas. Radiother. Oncol. 2011, 98, 1-14.
9. Addeo, R.; Caraglia, M.; de Santi, S.; Montella, L.; Abbruzzese, A.; Parlato, C.; Vincenzi, B.; Carraturo, M.; Faiola, V.; Genovese, M. et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J. Neurooncol. 2011, 102, 417-424.
10. I.R.I.S. Cancer Treatment Division. Fotemustine Investigator's Brochure, Version No. 3; Servier Laboratories: Orleans, France, 15 September 1999.
11. Deloffre, P.; Paraire, M.; Bizzari, J.P. Muphoran (fotémustine), une nouvelle nitrosourée: études précliniques. Cancer Commun. 1990, 4, 7-16.
12. Filippeschi, S.; Colombo, T.; Bassini, D. Antitumor activity of the novel nitrosourea S 10036 in rodent tumors. Anticancer Res. 1998, 8, 1351-1354.
13. Fischel, J.L.; Formento, P.; Etienne, M.C.; Gioanni, J.; Frenay, M.; Deloffre, P.; Bizzari, J.P.; Milano, G. In vitro chemosensitivity testing of fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother. Pharmacol. 1990, 25, 337-341.
14. Vassal, G.; Boland, I.; Terrier-Lacombe, M.J.; Watson, A.J.; Margison, G.P.; Vénuat, A.M.; Morizet, J.; Parker, F.; Lacroix, C.; Lellouch-Tubiana, A. et al. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin. Cancer Res. 1998, 4, 463-468.
15. Frenay, M.; Giroux, B.; Khoury, S.; Derlon, J.M.; Namer, M. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur. J. Cancer 1991, 27, 852-856.
16. Khayat, D.; Giroux, B.; Berille, J.; Cour, V.; Gerard, B.; Sarkany, M.; Bertrand, P.; Bizzari, J.P. Fotemustine in the treatment of brain primary tumour and metastases. Cancer Invest. 1994, 12, 414-420.
17. Malhaire, J.P.; Lucas, B.; Simon, H.; Person, H.; Dam-Hieu, P.; Labat, J.P. Fotemustine (muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull. Cancer 1999, 86, 289-294.
18. Mousseau, M.; Swiercz, V.; Rougny, M.; Boutonnat, J.; Méchin, I.; Chinal, J. Fotemustine in recurrent supratentoriel malignant gliomas. Drugs Today 1996, 32, 43-50.
19. Boiardi, A.; Antonio Silvani, A.; Ciusani, E.; Watson, A.; Margison, G.; Berger, E.; Lucas, C.; Giroux, B. Fotemustine combined with procarbazine in recurrent malignant gliomas: A phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. J. Neurooncol. 2001, 52, 149-156.
20. Fazeny-Dörner, B.; Veitl, M.; Wenzel, C.; Piribauer, M.; Rössler, K.; Dieckmann, K.; Ungersböck, K.; Marosi, C. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 2003, 14, 437-442.
21. Scoccianti, S.; Detti, B.; Sardaro, A.; Iannalfi, A.; Meattini, I.; Leonulli, B.G.; Borghesi, S.; Martinelli, F.; Bordi, L.; Ammannati, F. et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: A single institution experience. Anticancer Drugs 2008, 19, 613-620.
22. Brandes, A.; Tosoni, A.; Franceschi, E.; Blatt, V.; Santoro, A.; Faedi, M.; Amistà, P.; Gardiman, M.; Labianca, R.; Bianchini, C. et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: A phase II trial of gruppo italiano cooperativo di neuro-oncologia (GICNO). Cancer Chemother. Pharmacol. 2009, 64, 769-775.
23. Fabrini, M.G.; Silvano, G.; Lolli, I.; Perrone, F.; Marsella, A.; Scotti, V.; Cionini, L. A Multiinstitutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol. 2009, 92, 79-86.
24. Silvani, A.; Lamperti, E.; Gaviani, P.; Eoli, M.; Fiumani, A.; Salmaggi, A.; Falcone, C.; Filippini, G.; Botturi, A.; Boardi, A. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J. Neurooncol. 2008, 87, 143-151.
25. Fabi, A.; Metro, G.; Russillo, M.; Vidiri, A.; Carapella, C.M.; Maschio, M.; Cognetti, F.; Jandolo, B.; Mirri, M.A.; Sperduti, I. et al. Treatment of recurrent malignant gliomas with fotemustine monotherapy: Impact of dose and correlation with MGMT promoter methylation. BMC Cancer 2009, 9, 101.
26. Fabi, A.; Metro, G.; Vidiri, A.; Lanzetta, G.; Carosi, M.; Telera, S.; Maschio, M.; Russillo, M.; Sperduti, I.; Carapella, C. et al. Low-dose fotemustine for recurrent malignant glioma: A multicenter phase II study. J. Neurooncol. 2010, 100, 209-215.
27. Chinot, O.; de La Motte Rouge, T.; Moore, N.; Zeaiter, A.; Das, A.; Phillips, H.; Modrusan, Z.; Cloughesy, T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 2011, 28, 334-340.
28. Soffietti, R.; Trevisan, E.; Ruda, R.; Bertero, L.; Bosa, C.; Fabrini, M.G.; Lolli, I. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol. 2011, 29, Abstract 2027.